Representative Image
(Gil Cohen Magen/Xinhua/IANS)
The International Vaccine Institute (IVI) has announced that the first participant received Bharat Biotech’s Chikungunya vaccine candidate (BBV87) in Phase II/III clinical trial in Costa Rica.
This marks the beginning of a multi-country study led by IVI in partnership with Bharat Biotech and funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology, India.
IVI is advancing clinical development of BBV87 through a Phase II/III randomized, controlled trial to evaluate the safety and immunogenicity of a 2-dose regimen of BBV87 Chikungunya vaccine in healthy adults at 9 clinical trial sites across 5 countries with endemic Chikungunya. In addition to the trial at Clinica San Agustin in Costa Rica, trials are expected to begin in Panama and Colombia by…
